Month: February 2025

Fourth Quarter Net Sales Increased 20% with Full Year Increasing 5% to $516 million benefiting from Vita Coco Coconut Water growth of 10%  Full Year Net Income Increased $9 million to $56 million and Non-GAAP Adjusted EBITDA1 Increased $16 million to $84 million For Fiscal Year 2025, Expect Net Sales between $555 and $570 million and Adjusted EBITDA2 between $86 and $92 million NEW YORK, Feb. 26, 2025 (GLOBE NEWSWIRE) — The Vita Coco Company, Inc. (NASDAQ:COCO) (“Vita Coco” or “the Company”), a leading high-growth platform of better-for-you beverage brands, today announced financial results for the fourth quarter and full year ended December 31, 2024. Fourth Quarter and Full Year 2024 Highlights Compared to Prior YearNet sales increased 20% in the fourth quarter to $127 million resulting in full year net sales of $516 million. Vita...

Worldwide revenue of $391.1 million and $1.53 billion for the fourth quarter and full year 2024 Free cash flow was $141.4 million and $493.1 million for the fourth quarter and full year 2024 GAAP fully diluted loss per share of $(0.17) and earnings per share of $4.36 for the fourth quarter and full year 2024 Adjusted fully diluted earnings per share of $1.59 and $6.76 for the fourth quarter and full year 2024 PYLARIFY exceeds $1 billion in net sales and becomes first ever blockbuster radiodiagnostic Company announces a series of strategic asset and in-licensing deals that is expected to diversify its portfolio with early- to late-stage assets that position the company for continued growth in high potential markets Company provides full year 2025 revenue and adjusted diluted earnings per share guidanceBEDFORD, Mass., Feb. 26, 2025 ...

Achieved record positive Adjusted EBITDA* of $20 million for FY2024 (net loss of $8.3 million), exceeding latest guidance of $17-19 millionAchieved record quarterly revenue of $25 million and annual revenue of $85.9 millionNew credit facilities’ favorable interest rates and amortization schedules free up approximately $19 million in cash in 2025In-licensed two new Ionis assets in Canada to drive long-term growthMONTREAL, Feb. 26, 2025 (GLOBE NEWSWIRE) — Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a specialty biopharmaceutical company focused on the commercialization of innovative therapies that have the potential to redefine standards of care, today reported business highlights and financial results for the fourth quarter and full year of fiscal year 2024, ended November...

2024 Net Income of $19.2 million Annual EBITDA1 of $68.8 million and Free Cash Flow to Equity1 of $27.8 million 14th Quarterly Dividend of Cdn$0.03 Declared $21.2 million Returned to Shareholders in 2024 VANCOUVER, British Columbia, Feb. 26, 2025 (GLOBE NEWSWIRE) — Amerigo Resources Ltd. (TSX: ARG; OTCQX: ARREF) (“Amerigo” or the “Company”) is pleased to announce financial results for the year and three months (“Q4-2024”) ended December 31, 2024. Dollar amounts in this news release are in U.S. dollars unless indicated otherwise. Amerigo’s annual financial results included annual net income of $19.2 million, earnings per share (“EPS”) of $0.12, EBITDA1 of $68.8 million and free cash flow to equity1 (“FCFE1”) of $27.8 million. In 2024, Amerigo returned $21.2 million to shareholders, including Cdn$.16 per share of quarterly and performance...

Consolidated revenues were $736 million, up 8.6% on a consolidated and an organic constant currency (OCC) basis for the fourth quarter of 2024. For the full year 2024, consolidated revenues were $2,882 million, up 7.5% and up 7.1% on an OCC basis. Income from continuing operations was $204 million, up 11.6% for the fourth quarter of 2024. Adjusted EBITDA, a non-GAAP measure, was $398 million, up 9.9%, and up 13.5% on an OCC basis. For the full year 2024, income from continuing operations was $951 million, up 23.7%, while adjusted EBITDA was $1,576 million, up 9.9%, on a consolidated and OCC basis. Diluted GAAP earnings per share from continuing operations (diluted EPS attributable to Verisk) were $1.44 for the fourth quarter of 2024, up 15.2%. Diluted adjusted earnings per share from continuing operations (diluted adjusted EPS), a non-GAAP...